Prognostic Factors of Pacing-Induced Cardiomyopathy

0
0
0

Prognostic Factors of Pacing-Induced Cardiomyopathy

Cardiac pacing remains a cornerstone therapy for managing bradyarrhythmias, with millions of pacemakers implanted globally each year. While pacemakers effectively restore heart rate and prevent symptomatic bradycardia, long-term right ventricular (RV) pacing has been implicated in left ventricular (LV) electromechanical dyssynchrony, leading to impaired systolic function and heart failure—a condition termed pacing-induced cardiomyopathy (PICM). This study investigates the prognostic factors that identify patients at higher risk of developing PICM following pacemaker implantation, offering critical insights into early risk stratification and potential preventive strategies.

Background and Clinical Significance

PICM arises from chronic RV pacing, which disrupts the physiological sequence of ventricular activation. Instead of the coordinated contraction enabled by the native His-Purkinje system, RV pacing generates an abnormal electrical activation pattern, starting from the RV apex or septum and spreading laterally. This dyssynchrony redistributes myocardial strain, reduces LV torsion, and impairs contractility, ultimately diminishing LV ejection fraction (LVEF). Despite advancements in pacemaker technology, PICM remains an underrecognized complication, with reported incidences ranging from 5.9% to 39%, depending on diagnostic criteria.

The clinical implications are profound: patients developing PICM face higher hospitalization rates, increased mortality, and potential need for device upgrades to cardiac resynchronization therapy (CRT). Current guidelines lack clear recommendations for prophylactic CRT in patients with normal baseline LVEF, emphasizing the need to identify high-risk subgroups. This study bridges this gap by validating pre-implantation prognostic factors predictive of PICM.

Study Design and Methodology

Patient Cohort and Inclusion Criteria

This observational analysis evaluated 363 consecutive patients who underwent pacemaker implantation at Beijing Anzhen Hospital between January 2013 and June 2016. After exclusions for pre-existing LV dysfunction (LVEF <55%), incomplete data, or confounding conditions (e.g., valvular disease, frequent ventricular arrhythmias), 256 patients were included. All participants had normal LVEF (≥55%) at baseline and received either single-chamber (n=28) or dual-chamber (n=228) pacemakers with rate-responsive functionality.

Data Collection and Outcomes

Baseline demographics, clinical characteristics, and pacing parameters were extracted from hospital records. Key variables included:

  • Paced QRS duration: Measured from post-implantation electrocardiograms.
  • Ventricular pacing percentage: Derived from device interrogations.
  • LVEF: Assessed via standardized echocardiography pre-implantation and at 1-year follow-up.

PICM was defined as either:

  1. A post-implantation LVEF <45%, or
  2. A relative decline in LVEF ≥10% from baseline, after excluding alternative etiologies (e.g., ischemia, metabolic disorders).

Statistical Analysis

Univariate and multivariate Cox proportional hazard models identified prognostic factors. Dose-response analysis evaluated thresholds for paced QRS duration and ventricular pacing percentage. Stratified analyses further validated these thresholds.

Key Findings

Incidence and Baseline Characteristics

Among 256 patients, 23 (8.98%) developed PICM within 1 year. The mean LVEF in PICM patients dropped from 62.3% pre-implantation to 42.7% post-implantation (range: 9–46% absolute decline). Patients with PICM exhibited distinct characteristics compared to the non-PICM group (Table 1):

  • Sex: 69.6% of PICM patients were male vs. 47.6% in non-PICM (P=0.047).
  • Paced QRS duration: 153.4 ± 11.5 ms in PICM vs. 141.7 ± 13.4 ms in non-PICM (P<0.001).
  • Ventricular pacing burden: 60.6 ± 25.6% in PICM vs. 38.2 ± 31.5% in non-PICM (P=0.001).

Prognostic Factors in Univariate and Multivariate Analysis

Univariate analysis identified four significant predictors of PICM:

  1. Male sex (HR: 1.50, 95% CI: 1.36–1.66).
  2. Presence of advanced atrioventricular block (AVB).
  3. Prolonged paced QRS duration (HR: 2.12 per 1 ms increase).
  4. Higher ventricular pacing percentage (HR: 1.99 per 1% increase).

In multivariate Cox regression, three independent predictors emerged:

  1. Male sex (HR: 1.20, 95% CI: 1.09–1.33; P<0.005).
  2. Paced QRS duration (HR: 1.95 per 1 ms increase; 95% CI: 1.80–2.12; P<0.001).
  3. Ventricular pacing percentage (HR: 1.65 per 1% increase; 95% CI: 1.51–1.79; P<0.001).

Dose-Response Relationships

Dose-response curves revealed nonlinear associations:

  • Paced QRS duration: Risk of PICM escalated sharply beyond 140 ms. Patients with QRS ≥160 ms had a 26.1% incidence vs. 8.7% for QRS <140 ms.
  • Ventricular pacing burden: PICM incidence rose exponentially above 27.2%, reaching 26.1% in patients with ≥87.2% pacing.

Stratified analyses confirmed these thresholds, with adjusted hazard ratios of 1.45 per 1 ms increase in QRS (95% CI: 1.21–1.74) and 1.87 per 1% increase in pacing burden (95% CI: 1.72–2.03).

Discussion

Clinical Implications of Prognostic Factors

This study underscores paced QRS duration and ventricular pacing percentage as the most sensitive predictors of PICM. Prolonged QRS reflects increased electromechanical dyssynchrony, while high pacing burden exacerbates cumulative LV remodeling. Male predisposition may relate to sex-specific differences in myocardial remodeling or comorbidities, though further mechanistic studies are needed.

Comparison with Existing Evidence

The 8.98% incidence aligns with prior reports (e.g., 9% in Yu et al.), but contrasts with higher rates in cohorts with longer follow-up. The PACE trial demonstrated LVEF declines to 54.8% after 1 year of RV pacing, consistent with this study’s findings. Notably, even modest pacing burdens (27.2–87.2%) conferred significant risk, challenging the conventional 40% threshold proposed in earlier studies.

Mechanistic Insights

RV pacing alters LV torsion and strain distribution, inducing regional hypoperfusion and metabolic stress. Animal models reveal mitochondrial dysfunction and apoptotic signaling in PICM, suggesting irreversible cellular damage beyond electrical dyssynchrony. These findings highlight the need for early intervention in high-risk patients.

Limitations and Future Directions

This study’s single-center design and 1-year follow-up limit generalizability. Longer observation periods may reveal higher PICM incidence, as seen in studies with 4–15 year follow-ups. Additionally, lead position (apical vs. septal) lacked echocardiographic confirmation, though prior randomized trials (e.g., PROTECT-PACE) showed no benefit from septal pacing.

Future research should explore:

  • Prophylactic CRT or His-bundle pacing in high-risk subgroups.
  • Biomarkers of early myocardial remodeling.
  • Sex-specific pathophysiological mechanisms.

Conclusion

This study validates paced QRS duration and ventricular pacing percentage as critical prognostic markers for PICM. Integrating these parameters into pre-implantation risk assessments could guide personalized pacing strategies, such as upfront CRT in high-risk patients, to mitigate long-term morbidity. Clinicians should prioritize vigilant monitoring and early echocardiography in patients with prolonged QRS (>140 ms) or high pacing burdens (>27.2%) to detect PICM promptly.

doi.org/10.1097/CM9.0000000000000856

Was this helpful?

0 / 0